156 related articles for article (PubMed ID: 21684635)
1. [From genetics to genomics in the rational design of new Mycobacterium tuberculosis vaccines].
Bocanegra-García V; Valencia-Delgadillo J; Cruz-Pulido W; Cantú-Ramírez R; Rivera-Sánchez G; Palma-Nicolás JP
Enferm Infecc Microbiol Clin; 2011 Oct; 29(8):609-14. PubMed ID: 21684635
[TBL] [Abstract][Full Text] [Related]
2. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of vaccines against tuberculosis in the relation to genetic variability of Mycobacterium bovis BCG strains].
Prygiel M; Janaszek-Seydlitz W; Bucholc B
Przegl Epidemiol; 2011; 65(4):621-8. PubMed ID: 22390050
[TBL] [Abstract][Full Text] [Related]
6. [Strategies for the development of new tuberculosis vaccines].
Fattorini L
Minerva Med; 2007 Apr; 98(2):109-19. PubMed ID: 17519853
[TBL] [Abstract][Full Text] [Related]
7. Recombinant and synthetic peptides to identify Mycobacterium tuberculosis antigens and epitopes of diagnostic and vaccine relevance.
Mustafa AS
Tuberculosis (Edinb); 2005; 85(5-6):367-76. PubMed ID: 16253561
[TBL] [Abstract][Full Text] [Related]
8. New tuberculosis vaccines.
Martín Montañés C; Gicquel B
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 1():57-62. PubMed ID: 21420568
[TBL] [Abstract][Full Text] [Related]
9. Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development.
Dietrich J; Doherty TM
APMIS; 2009 May; 117(5-6):440-57. PubMed ID: 19400867
[TBL] [Abstract][Full Text] [Related]
10. Vaccine approaches to prevent tuberculosis.
Wiker HG; Mustafa T; Målen H; Riise AM
Scand J Immunol; 2006 Sep; 64(3):243-50. PubMed ID: 16918693
[TBL] [Abstract][Full Text] [Related]
11. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis.
Sun R; Skeiky YA; Izzo A; Dheenadhayalan V; Imam Z; Penn E; Stagliano K; Haddock S; Mueller S; Fulkerson J; Scanga C; Grover A; Derrick SC; Morris S; Hone DM; Horwitz MA; Kaufmann SH; Sadoff JC
Vaccine; 2009 Jul; 27(33):4412-23. PubMed ID: 19500523
[TBL] [Abstract][Full Text] [Related]
12. The safety of post-exposure vaccination of mice infected with Mycobacterium tuberculosis.
Derrick SC; Perera LP; Dheenadhayalan V; Yang A; Kolibab K; Morris SL
Vaccine; 2008 Nov; 26(48):6092-8. PubMed ID: 18809446
[TBL] [Abstract][Full Text] [Related]
13. Immunoprophylaxis of tuberculosis: an update of emerging trends.
Singhal N; Bisht D; Joshi B
Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):97-106. PubMed ID: 20140756
[TBL] [Abstract][Full Text] [Related]
14. Difference in TB10.4 T-cell epitope recognition following immunization with recombinant TB10.4, BCG or infection with Mycobacterium tuberculosis.
Billeskov R; Grandal MV; Poulsen C; Christensen JP; Winther N; Vingsbo-Lundberg C; Hoang TT; van Deurs B; Song YH; Aagaard C; Andersen P; Dietrich J
Eur J Immunol; 2010 May; 40(5):1342-54. PubMed ID: 20186878
[TBL] [Abstract][Full Text] [Related]
15. Delivery of a multivalent scrambled antigen vaccine induces broad spectrum immunity and protection against tuberculosis.
West NP; Thomson SA; Triccas JA; Medveczky CJ; Ramshaw IA; Britton WJ
Vaccine; 2011 Oct; 29(44):7759-65. PubMed ID: 21846485
[TBL] [Abstract][Full Text] [Related]
16. A novel DNA vaccine containing multiple TB-specific epitopes cast in a natural structure elicits enhanced Th1 immunity compared with BCG.
Gao H; Li K; Yu S; Xiong S
Microbiol Immunol; 2009 Oct; 53(10):541-9. PubMed ID: 19780967
[TBL] [Abstract][Full Text] [Related]
17. Re-formulation of selected DNA vaccine candidates and their evaluation as protein vaccines using a guinea pig aerosol infection model of tuberculosis.
Vipond J; Clark SO; Hatch GJ; Vipond R; Marie Agger E; Tree JA; Williams A; Marsh PD
Tuberculosis (Edinb); 2006; 86(3-4):218-24. PubMed ID: 16520093
[TBL] [Abstract][Full Text] [Related]
18. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
[TBL] [Abstract][Full Text] [Related]
19. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.
Andersen CS; Dietrich J; Agger EM; Lycke NY; Lövgren K; Andersen P
Infect Immun; 2007 Jan; 75(1):408-16. PubMed ID: 17074845
[TBL] [Abstract][Full Text] [Related]
20. The second Geneva Consensus: Recommendations for novel live TB vaccines.
Walker KB; Brennan MJ; Ho MM; Eskola J; Thiry G; Sadoff J; Dobbelaer R; Grode L; Liu MA; Fruth U; Lambert PH
Vaccine; 2010 Mar; 28(11):2259-70. PubMed ID: 20074686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
